Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × tucatinib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Colorectal Neoplasms 4 Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Meningeal Neoplasms 1 Hemangiosarcoma 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Breast Cancer 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Brain Neoplasms 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

Specimen Handling 38 pembrolizumab 36 Biopsy 34 Magnetic Resonance Spectroscopy 30 Nivolumab 19 Paclitaxel 15 Radiosurgery 11 Gemcitabine 11 Carboplatin 11 trastuzumab deruxtecan 10 Fulvestrant 10 Capecitabine 10 Taxes 9 Pemetrexed 9 Leucovorin 9 Irinotecan 9 Ipilimumab 9 Fluorouracil 9 Cisplatin 9 Drug Therapy 8 Cyclophosphamide 8 Cetuximab 8 130-nm albumin-bound paclitaxel 8 atezolizumab 7 abemaciclib 7 Oxaliplatin 7 palbociclib 6 X-Rays 6 Trastuzumab 6 Standard of Care 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07193394 2026-02-23

H3RAKLES

Institut Curie

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡